ПРОГРЕССивная тактика антигипертензивной терапии для вторичной профилактики инсульта: сохраняется ли проблема выбора?

1. Murray C.J.L., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436–42.
2. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypert 2007; 25: 1105–87.
3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
4. Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. Stroke 1993; 24: 1844–49.
5. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001; 357: 373–80.
6. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455–62.
7. The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke 1988; 19: 123–7.
8. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993; 24: 543–8.
9. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report . JAMA 2003; 289: 2560–72.
10. Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–26.
11. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
12. Boutitie F, Oprisiu R, Achard JM et al. Does angiotensin II formation change by antihypertensive drugs, aff ect the risk of stroke? J Hypertens 2007; 25: 1543–53.
13. Bosch JJ, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699–702.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
15. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225–37.
16. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
17. Bugnicourt JM, Chillon JM, Canaple S et al. Stroke secondary prevention and blood pressure reduction: an observational study of the use of PROGRESS therapy. Fundam Clin Pharmacol 2008; 22: 217–22.
18. Fox K. Contribution of perindopril to cardiology: 20 years of success. Eur Heart J 2007; 9 (Suppl E): E10–E19.
19. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004–2006. Med J Aust 2008; 188: 224–7.
20. Telejko E. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007; 23: 953–60.
21. Bardage C, Isacson DG. Self-reported side-effects of antihypertensive drugs: an epidemiological study on prevalence and impact on health-state utility. Blood Press 2000; 9: 328–34.
22. Kjellgren KI, Ahlner J, Dahlof B et al. Perceived symptoms amongst hypertensive patients in routine clinical practice–a population-based study. J Internal Med 1998; 244: 325–32.

С.Р.Гиляревский